

# COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era

Tuğçe Eşkazan<sup>1</sup>, Gökhan Aygün<sup>2</sup>, Oğuz Kağan Bakkaloğlu<sup>1</sup>, Enes Ali Kurt<sup>1</sup>, Okan Kadir Nohut<sup>3</sup>, Selçuk Candan<sup>1</sup>, Uğur Önal<sup>1</sup>, Yusuf Erzin<sup>1</sup>, Ali İbrahim Hatemi<sup>1</sup>, Aykut Ferhat Çelik<sup>1</sup>

<sup>1</sup>Division of Gastroenterology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, Türkiye

<sup>2</sup>Department of Infectious Diseases and Clinical Microbiology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye

<sup>3</sup>İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Fikret Biyal Central Research Laboratory, İstanbul, Türkiye

In Volume 4, Issue 1 of the Journal of Enterocolitis, the article entitled “COVID-19 Seroprevalence and Risk Factors in Inflammatory Bowel Disease Patients Receiving Immunosuppressive Treatment in the Pre-Vaccine Era” was published with an error in the Funding statement.

The Funding statement was incorrectly reported to the journal as: “The authors declared that this study received no financial support.”

The correct Funding statement, as provided now by the authors, is as follows:

“This work was supported by the Scientific Research Projects Coordination Unit of Istanbul University-Cerrahpaşa, Faculty of Medicine (Project ID: 35389; Project Code: TSA-2021:35389) under the scope of a General Research Project.”

**Corresponding author:** : Tuğçe Eşkazan, e-mail: tugce\_clskn@hotmail.com

DOI:1014744/Jenterocolitis.2025.99310



Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.